Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › NBP

NovaBridge Biosciences

NBP Lead: Phase 2 4 Biotech Distilled articles ↓ 31 filings & releases ↓ Cash $211M (Dec 31, 2025) ↓ 4 verdicts ↓
OncologyOphthalmology Protein

Market cap $106M 116.0M shares (vendor count, Nov 7, 2026) × $0.910 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-04-07

Catalyst timeline

3 trackedQuarter catalyst calendar →
  1. Uliledlimab Ph1 readout2H 2026Uliledlimab Ph1 readout, 2H 2026, material
  2. Givastomig Ph2 readout2027Givastomig Ph2 readout, 2027, notable
  3. VIS-101 Ph3 start2027VIS-101 Ph3 start, 2027, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

VIS-102

HT006.2.2
Protein Target: NGF
  • Neurotrophic Keratitis Phase 1 Wuhan Hiteck Biological Pharma

Capital (as filed)

Cash
$211M cash and cash equivalents · Dec 31, 2025 (20-F)
Short-term investments
$210K Dec 31, 2025
As stated in coverage
$191M cash per the update of Oct 26, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (4)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (4 calls)

Every verdict Biotech Distilled has published on NovaBridge Biosciences, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-20 Watch NovaBridge Biosciences (NBP) — Scientific Deep Dive for Givastomig, VIS-101 and Pipeline Products Best-in-class-looking givastomig Phase 1b data at a below-net-cash valuation is too interesting to pass, but 50/50 ABL Bio economics, a crowded Claudin 18.2 field led by Phase 3 ADCs, real dilution/funding risk, and a CBC-controlled China-heritage shell with no U.S. specialist ownership keep it off Buy.
  2. 2026-06-30 Speculative buy speculative UPDATE: NovaBridge Biosciences (NBP) - The CBC Grip Loosens New CEO with a partnership résumé materially increases the probability of the named upgrade trigger (ex-China givastomig deal) while the negative-EV setup has partially monetized; sizing small given the cash floor has thinned and the binary H2 2026 readout is now the dominant return driver.
  3. 2026-08-20 Speculative buy speculative UPDATE: NovaBridge Biosciences (NBP) - The Clock Gets a Date, The Cash Floor Gets Thinner ESMO October 25 date confirmed for the givastomig Phase 1b readout, but burn tripled to ~$66M annualized with admin exceeding R&D, the HKEx listing is written off, $25.1M of cash is a Level 3 mark, and the stock now trades above hard cash — asymmetry has narrowed materially with ESMO and a partnership as the remaining catalysts.
  4. 2026-10-27 Speculative buy speculative UPDATE: NovaBridge Biosciences (NBP) - The Median Held, The Stock Didn't The fragile-mPFS bear point is largely retired with 16.9-month PFS holding on 17.8-month follow-up and ORR rising to 79%, the stock has returned to a below-cash setup creating a free-call-option again, but no ex-China partner has emerged and the unfunded pivotal remains the key risk.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (31)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Jul 24, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)